Drug Monitoring Flashcards
TFT monitoring on levothyroxine
3 monthly until 2 stable results (close together and normal range) then annually
Amiodarone before treatment
and ongoing
CXR, ECG, U&E, LFT, TFT before treatment
TFT 6 monthly
Clozapine FBC monitoring
Every week for 18 weeks
Then every 2 weeks up to 1 year
Then monthly after 1 year
ACEI monitoring
U&E before starting and increasing dose, also 1-2 weeks after starting
Monitoring benefit of furesemide
Daily weights
Atorvastatin monitoring
Cholesterol, LFT, U&E, TFT before starting
LFTs 3 months and 12 months
CK in patients before starting with unexplained muscule pain
When to stop statins
LFT 3x upper normal reference range
ACEI electrolyte disturbance
Hyperkalaemia and AKI
Hba1c target concentration
48 mmol/L
Oxygen monitoring
Arterial blood gases (hypercapnic respiratory failure)
Rivaroxaban
Patient reported symptoms of anaemia
COCP
Weight and BP
IV aminophylline
4-6 hours after treatment
Oral aminophylline
5 days after treatment then 3 days after dose change
Lithium patient parameters
U&E, TFT, FBC, BMI, ECG (if risk factors) before treatment
U&E, TFT, BMI every 6 months
Lithium level monitoring
12 hours after dose aim for 0.4-1mmol/L (0.8-1 in acute mania)
Monitoring weekly after dose change until stable
Then 3 monthly for first year
Then 6 monthly (if narrower target range remain 3 monthly)
Methotrexate monitoring
FBC, U&E, LFT every 1-2 weeks until stable
Then every 2-3 months
Sodium valproate
FBC and LFT before therapy
LFT 6 monthly
Fluid bolus
HR and BP
Response after antibiotics
CRP after few days
Enoxaparan
Platalets before initiation and after 4 days
